Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?
Nils Bomer1, Mario G Pavez-Giani1, Niels Grote Beverborg1
1Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Journal of Internal Medicine
|February 9, 2022
Summary
Micronutrient deficiencies impair heart energy production in heart failure patients. Supplementing these essential nutrients may offer a new therapeutic strategy for improving cardiac function.
Area of Science:
- Cardiology
- Mitochondrial Medicine
- Nutritional Science
Background:
- Heart failure (HF) is a major clinical challenge with limited therapeutic options.
- Cardiac dysfunction in HF is linked to metabolic issues, including impaired energy substrate utilization and mitochondrial dysfunction.
- This leads to cardiac energy deprivation and progressive heart muscle damage.
Purpose of the Study:
- To investigate the role of micronutrient deficiencies in heart failure pathophysiology.
- To explore the potential of micronutrient supplementation as a therapeutic approach for heart failure.
Main Methods:
- Review of evidence establishing the link between cardiac performance and metabolic perturbations.
- Analysis of the role of essential micronutrients in mitochondrial ATP production.
- Examination of micronutrient status in heart failure patients.
Main Results:
- Heart failure patients frequently exhibit deficiencies in key micronutrients (e.g., coenzyme Q10, zinc, copper, selenium, iron).
- Micronutrient deficiencies significantly impair mitochondrial energy production, contributing to cardiac dysfunction.
- This suggests a "defective engine" model rather than simply an "out of fuel" model for the failing heart.
Conclusions:
- Micronutrient deficiency is a critical factor in heart failure, impacting mitochondrial function.
- Supplementation with a combination of micronutrients may represent a promising therapeutic strategy for heart failure patients.
- Further research into micronutrient packages for heart failure treatment is warranted.
Related Concept Videos
01:27Heart Failure I: Introduction
107
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
107
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
01:29Heart Failure II: Pathophysiology
91
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
91
01:46Electron Transport Chain: Complex I and II
15.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.2K
01:22Heart Failure VI: Adjunct Therapies
47
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
01:30Heart Failure VII: Nursing Interventions
163
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
163